DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety

Reuters12-17

DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety

DexCom Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products without FDA approval, which made the devices less reliable and posed significant health risks to users. It is also claimed that the company overstated the reliability, accuracy, and functionality of the G7 device, while downplaying the severity of the issues and risks associated with the altered products. As a result, DexCom is accused of making materially false or misleading public statements, exposing the company to regulatory scrutiny and potential financial and reputational harm. The litigation is being handled by the law firm Levi & Korsinsky.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1118548) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592997251?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592997251","market":"us","top_or_hot":-1,"title":"DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DexCom Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products without FDA approval, which made the devices less reliable and posed significant health risks to users. It is also claimed that the company overstated the reliability, accuracy, and functionality of the G7 device, while downplaying the severity of the issues and risks associated with the altered products. As a result, DexCom is accused of making materially false or misleading public statements, exposing the company to regulatory scrutiny and potential financial and reputational harm. The litigation is being handled by the law firm Levi &amp; Korsinsky.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1118548) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DexCom Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products without FDA approval, which made the devices less reliable and posed significant health risks to users. It is also claimed that the company overstated the reliability, accuracy, and functionality of the G7 device, while downplaying the severity of the issues and risks associated with the altered products. As a result, DexCom is accused of making materially false or misleading public statements, exposing the company to regulatory scrutiny and potential financial and reputational harm. The litigation is being handled by the law firm Levi &amp; Korsinsky.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1118548) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BMPRXN33.USD","symbol_name":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5HrDc8:1","article_id":"2592997251","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592997251","pubTimestamp":1765975336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DexCom Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products without FDA approval, which made the devices less reliable and posed significant health risks to users. It is also claimed that the company overstated the reliability, accuracy, and functionality of the G7 device, while downplaying the severity of the issues and risks associated with the altered products. As a result, DexCom is accused of making materially false or misleading public statements, exposing the company to regulatory scrutiny and potential financial and reputational harm. The litigation is being handled by the law firm Levi & Korsinsky.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4551":"寇图资本持仓","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","DXCM":"德康医疗","BK4548":"巴美列捷福持仓","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H"},"translate_title":"DexCom因涉嫌对血糖监测仪安全性做出虚假陈述而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":0.9},"content_text":"DexCom Faces Class Action Lawsuit Over Alleged False Statements on Glucose Monitor Safety\n    \n\n        DexCom Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products without FDA approval, which made the devices less reliable and posed significant health risks to users. It is also claimed that the company overstated the reliability, accuracy, and functionality of the G7 device, while downplaying the severity of the issues and risks associated with the altered products. As a result, DexCom is accused of making materially false or misleading public statements, exposing the company to regulatory scrutiny and potential financial and reputational harm. The litigation is being handled by the law firm Levi & Korsinsky.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1118548) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592997251","isCrawlerRequest":true}